FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380201468> ?p ?o ?g. }

• W4380201468 endingPage "1262" @default.
• W4380201468 startingPage "1249" @default.
• W4380201468 abstract "Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to reduce the risk of cardiovascular complications, which largely drive diabetes' health and economic burdens. Trial results indicated that SGLT2i are cost effective. However, these findings may not be generalizable to the real-world target population. This study aims to evaluate the cost effectiveness of SGLT2i in a routine care type 2 diabetes population that meets Dutch reimbursement criteria using the MICADO model.Individuals from the Hoorn Diabetes Care System cohort (N = 15,392) were filtered to satisfy trial inclusion criteria (including EMPA-REG, CANVAS, and DECLARE-TIMI58) or satisfy the current Dutch reimbursement criteria for SGLT2i. We validated a health economic model (MICADO) by comparing simulated and observed outcomes regarding the relative risks of events in the intervention and comparator arm from three trials, and used the validated model to evaluate the long-term health outcomes using the filtered cohorts' baseline characteristics and treatment effects from trials and a review of observational studies. The incremental cost-effectiveness ratio (ICER) of SGLT2i, compared with care-as-usual, was assessed from a third-party payer perspective, measured in euros (2021 price level), using a discount rate of 4% for costs and 1.5% for effects.From Dutch individuals with diabetes in routine care, 15.8% qualify for the current Dutch reimbursement criteria for SGLT2i. Their characteristics were significantly different (lower HbA1c, higher age, and generally more preexisting complications) than trial populations. After validating the MICADO model, we found that lifetime ICERs of SGLT2i, when compared with usual care, were favorable (< €20,000/QALY) for all filtered cohorts, resulting in an ICER of €5440/QALY using trial-based treatment effect estimates in reimbursed population. Several pragmatic scenarios were tested, the ICERs remained favorable.Although the Dutch reimbursement indications led to a target group that deviates from trial populations, SGLT2i are likely to be cost effective when compared with usual care." @default.
• W4380201468 created "2023-06-11" @default.
• W4380201468 creator A5001619297 @default.
• W4380201468 creator A5004751798 @default.
• W4380201468 creator A5012179966 @default.
• W4380201468 creator A5029514302 @default.
• W4380201468 creator A5036192040 @default.
• W4380201468 creator A5036526464 @default.
• W4380201468 creator A5040944251 @default.
• W4380201468 creator A5041876856 @default.
• W4380201468 creator A5085784987 @default.
• W4380201468 creator A5087463771 @default.
• W4380201468 date "2023-06-10" @default.
• W4380201468 modified "2023-10-14" @default.
• W4380201468 title "Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry" @default.
• W4380201468 cites W1999347590 @default.
• W4380201468 cites W2015568638 @default.
• W4380201468 cites W2040905198 @default.
• W4380201468 cites W2048320234 @default.
• W4380201468 cites W2070921516 @default.
• W4380201468 cites W2082368581 @default.
• W4380201468 cites W2091237544 @default.
• W4380201468 cites W2102503717 @default.
• W4380201468 cites W2131649684 @default.
• W4380201468 cites W2146264128 @default.
• W4380201468 cites W2150959326 @default.
• W4380201468 cites W2157450846 @default.
• W4380201468 cites W2169355652 @default.
• W4380201468 cites W2171929509 @default.
• W4380201468 cites W2213466407 @default.
• W4380201468 cites W2232985297 @default.
• W4380201468 cites W2492672367 @default.
• W4380201468 cites W2618596952 @default.
• W4380201468 cites W2621728603 @default.
• W4380201468 cites W2626446274 @default.
• W4380201468 cites W2760970101 @default.
• W4380201468 cites W2788613077 @default.
• W4380201468 cites W2797514322 @default.
• W4380201468 cites W2884466498 @default.
• W4380201468 cites W2889216614 @default.
• W4380201468 cites W2898518424 @default.
• W4380201468 cites W2899677525 @default.
• W4380201468 cites W2899764361 @default.
• W4380201468 cites W2900413769 @default.
• W4380201468 cites W2903720206 @default.
• W4380201468 cites W2912910847 @default.
• W4380201468 cites W2914797732 @default.
• W4380201468 cites W2918911727 @default.
• W4380201468 cites W2921711486 @default.
• W4380201468 cites W2961971687 @default.
• W4380201468 cites W2962208232 @default.
• W4380201468 cites W2967498567 @default.
• W4380201468 cites W2975832089 @default.
• W4380201468 cites W2979648592 @default.
• W4380201468 cites W3006904682 @default.
• W4380201468 cites W3012131422 @default.
• W4380201468 cites W3014850063 @default.
• W4380201468 cites W3046406709 @default.
• W4380201468 cites W3046450221 @default.
• W4380201468 cites W3047318182 @default.
• W4380201468 cites W3114602469 @default.
• W4380201468 cites W3131557571 @default.
• W4380201468 cites W3153650031 @default.
• W4380201468 cites W3164570271 @default.
• W4380201468 cites W4200382660 @default.
• W4380201468 cites W4206321249 @default.
• W4380201468 cites W4224287318 @default.
• W4380201468 cites W4229629337 @default.
• W4380201468 cites W4281625765 @default.
• W4380201468 cites W4284978069 @default.
• W4380201468 doi "https://doi.org/10.1007/s40273-023-01286-3" @default.
• W4380201468 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37300652" @default.
• W4380201468 hasPublicationYear "2023" @default.
• W4380201468 type Work @default.
• W4380201468 citedByCount "0" @default.
• W4380201468 crossrefType "journal-article" @default.
• W4380201468 hasAuthorship W4380201468A5001619297 @default.
• W4380201468 hasAuthorship W4380201468A5004751798 @default.
• W4380201468 hasAuthorship W4380201468A5012179966 @default.
• W4380201468 hasAuthorship W4380201468A5029514302 @default.
• W4380201468 hasAuthorship W4380201468A5036192040 @default.
• W4380201468 hasAuthorship W4380201468A5036526464 @default.
• W4380201468 hasAuthorship W4380201468A5040944251 @default.
• W4380201468 hasAuthorship W4380201468A5041876856 @default.
• W4380201468 hasAuthorship W4380201468A5085784987 @default.
• W4380201468 hasAuthorship W4380201468A5087463771 @default.
• W4380201468 hasBestOaLocation W43802014681 @default.
• W4380201468 hasConcept C112930515 @default.
• W4380201468 hasConcept C126322002 @default.
• W4380201468 hasConcept C134018914 @default.
• W4380201468 hasConcept C138816342 @default.
• W4380201468 hasConcept C159110408 @default.
• W4380201468 hasConcept C160735492 @default.
• W4380201468 hasConcept C162324750 @default.
• W4380201468 hasConcept C2777180221 @default.
• W4380201468 hasConcept C2779703844 @default.
• W4380201468 hasConcept C2908647359 @default.
• W4380201468 hasConcept C3019080777 @default.

• next